BioMarin Expects Pre-tax Charges Related to Alesta Acquisition to Impact Q3 Adjusted EPS
MT newswire2026/10/06 21:5605:56 PM EDT, 10/06/2026 (MT Newswires) -- BioMarin Pharmaceutical (BMRN) said in a late Tuesday regulatory filing that pre-tax charges of $283 million in acquired in-process research and development expense related to the acquisition of Alesta Therapeutics and the ongoing operating expenses will have an unfavorable impact of $1.50 on Q3 adjusted earnings per share. For the full year 2026, the company expects the acquisition to result in pre-tax charges of $320 million, expected to have a negative impact of $1.55 on annual adjusted EPS, according to the filing.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Jensen Huang's influence surpasses that of Nvidia— and that's exactly the problem
Jensen Huang has been the key driving force behind the massive expansion of AI infrastructure, with his personal credibility and authoritative decision-making deeply embedded in the narrative of the global tech market’s rise over the past three years. Now, as scandals emerge, Nvidia’s trading team is expected to become more conservative and slow down external financing commitments, which undoubtedly worsens the situation for neoclouds already facing tight funding.
Deutsche Bank made significant Q3 purchases of midstream AI application stocks: the three major cloud giants saw increased holdings, with Palantir (PLTR.US) and Salesforce (CRM.US) also favored.
Deutsche Bank has submitted its third quarter 13F holdings report for the period ending September 30, 2026.
Crypto prices
More
